1. United Kingdom Stocks

  2. •

    Technology services

  3. •

    Packaged software
Cambridge Cognition Holdings Plc

Cambridge Cognition Holdings Plc

LLSE:COG
28.00
GBX
0.00
(0.00%)
1.30BMarket Cap
May 05Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.31
0.35
0.3
0.35
0.33
0.3
0.22
0.23
0.32
0.4
0.39
0.27
0.22
- -
Basic EPS, GAAP
-0.21
-0.01
-0.05
0.01
-0.01
-0.07
-0.12
-0.01
0.01
-0.01
-0.1
-0.05
-0.04
- -
Free Cash Flow per Basic Share
-0.19
-0.05
-0.05
0.02
-0.03
-0.03
-0.1
0.03
0.12
0.05
-0.14
-0.08
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.13
0.12
0.08
0.14
0.15
-0.03
-0.04
- -
0.02
- -
0.04
0.08
0.06
0.06
Tangible Book Value per Share
0.11
0.1
0.06
0.13
0.13
-0.04
-0.05
-0.01
0.01
-0.04
-0.19
-0.08
-0.07
-0.07
Basic Weighted Avg Shares
13
16
17
19
20
21
23
30
31
31
35
39
43
44
Sales/Revenue/Turnover
4
6
5
7
7
6
5
7
10
13
14
10
9
- -
Operating Margin (%)
-71.31
-5.24
-17.2
1.69
-4.22
-24.7
-61.84
-9.55
2.62
-1.09
-13.68
-10.09
-13.17
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
- -
Net Income, GAAP
-3
- -
-1
- -
- -
-1
-3
- -
- -
- -
-4
-2
-2
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-68.97
-2.98
-15.51
3.96
-3.82
-23.51
-57.54
-6.5
4.46
-3.24
-25.96
-17.26
-17.82
- -
Working Capital
2
2
1
2
3
-1
-1
- -
- -
-2
-5
-4
-5
-5
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
1
- -
- -
Total Equity
2
2
1
3
3
-1
-1
- -
1
- -
1
3
3
3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-8.28
-45.18
12.58
-8.65
- -
- -
- -
130.62
-112.52
-509.14
-76.86
-52.71
- -

Capital Structure

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
1
1
1
LT Borrowings
1
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
42
42
47
Market Capitalization
16
13
13

Working Capital

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
4
4
3
Cash, Cash Equivalents & STI
1
- -
1
Accounts Receivable, Net
1
2
1
Inventories
- -
- -
- -
Total Current Liabilities
9
9
8
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
228.99%
465.08%
-10.95%
Free Cash Flow
-63.25%
-67.73%
-102.14%
Net Income, GAAP
45.69%
61.76%
-6.16%
Sales/Revenue/Turnover
9.06%
9.85%
-9.11%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
14
2024
- -
- -
10
2025
- -
- -
9

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.1
2024
- -
- -
-0.05
2025
- -
- -
-0.04

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Robert Roland Baker
Full Time Employees
74
Sector
Technology services
Industry
Packaged software
Address
Tunbridge Court Bottisham CAM United Kingdom CB25 9TU
IPO Date
Apr 18, 2013
Website
cambridgecognition.com
Similar Companies
Microsoft Corporation (NASDAQ:MSFT)
Palantir Technologies Inc. (NASDAQ:PLTR)
Nebius Group N.V. (NASDAQ:NBIS)
Oracle Corporation (NYSE:ORCL)
CoreWeave, Inc. (NASDAQ:CRWV)
ServiceNow, Inc. (NYSE:NOW)
Business
Cambridge Cognition Holdings Plc (AIM: COG.L) develops and commercializes digital neuroscience technologies for assessing brain health and cognition, offering touchscreen and voice-based cognitive assessments, electronic clinical outcomes assessment tools, decentralized clinical trial platforms, and healthcare solutions worldwide, principally in the United Kingdom, United States, Europe, Canada, and South Africa; core products include CANTAB Connect for touchscreen and customizable electronic questionnaires, Cognition Kit for high-frequency wearable and smartphone data collection, NeuroVocalix and Winterlight for speech analysis biomarkers, Clinpal and eCOA for electronic data capture and patient monitoring, eConsent for remote informed consent, and AQUA for ratings quality assurance, targeting therapeutic areas such as Alzheimer's disease, ADHD, depression, Parkinson's disease, schizophrenia, and traumatic brain injury across pharmaceutical clinical trials, academic research, and primary care settings. Founded in 2012 and headquartered at Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU, United Kingdom, the company traces its technology roots to the Cambridge Neuropsychological Test Automated Battery developed over 30 years ago by University of Cambridge researchers and has expanded through strategic acquisitions including eClinical Health for virtual trial capabilities and Winterlight Labs in 2022 for advanced voice biomarkers. Recent developments feature a 109% increase in new sales orders to £6.9m and order book growth to £16.4m for the six months ended 30 June 2025, alongside pursuits of partnerships in healthcare and consumer health markets, refreshed commercial team driving pipeline momentum at £32.5m, and board updates in November 2025 amid revenue guidance of £9.5-10.0m for full-year 2025 and improved profitability outlook for 2026.